We value your privacy

We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.

Evidence review · Healthy aging

Rapamycin (sirolimus) for longevity: what is known—and not known

A careful separation of approved medicine, animal aging science, early human studies, and claims that remain unproven.

Written by the Kindr Health Editorial & Clinical TeamMedically reviewed by Kindr Health Clinical Team Kindr Health Inc. organizational NPI 1609792902Published Last reviewed

Sirolimus, also called rapamycin, is an FDA-approved immunosuppressant for specific medical uses. It is not FDA approved to slow aging, extend lifespan, prevent age-related disease, or improve healthspan in otherwise healthy people. Animal longevity findings are important, but human evidence remains limited and does not establish a longevity benefit.

Immunosuppression carries serious risk

The Rapamune label has boxed warnings for increased susceptibility to infection and possible development of malignancies such as lymphoma and skin cancer. It also warns that use in liver or lung transplant patients is not recommended because safety and efficacy have not been established and excess mortality or graft-loss risks have been observed.

Other important risks include mouth ulcers, impaired wound healing, edema, high lipids, blood-count abnormalities, kidney toxicity in some combinations, lung toxicity, reproductive effects, interactions, and vaccine considerations. These risks cannot be assumed to disappear under an unapproved longevity regimen.

Current label check

The medication-specific claims on this page were checked against these current product labels on 2026-10-03. Longevity claims are labeled preclinical or early human evidence, not label claims.

Source: DailyMed, U.S. National Library of Medicine
Product labelLabel dateBoxed warning on that label
Sirolimus tablets2026-09-11Immunosuppression; not recommended in liver or lung transplant

Established evidence

What sirolimus is actually approved to treat

FDA-approved Rapamune is used for prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants and for treatment of lymphangioleiomyomatosis. Other sirolimus formulations and products can have different indications. Longevity is not among the approved uses.

Established evidence

Why aging researchers study mTOR

Sirolimus inhibits mechanistic target of rapamycin signaling, a nutrient-sensing network involved in cell growth, protein synthesis, metabolism, immune function, and autophagy. That biology makes mTOR scientifically relevant to aging, but a plausible mechanism is not proof of a safe clinical benefit.

Preclinical evidence

The animal longevity evidence

The National Institute on Aging Interventions Testing Program reported lifespan extension in genetically heterogeneous mice, including when rapamycin began later in life. Replicated animal findings justify research. They do not establish how benefits, timing, or risks translate to humans.

Limited human evidence

What human studies can—and cannot—tell us

Human studies have examined immune response, selected aging-related measures, and short-term or intermediate safety outcomes. A 2024 systematic review found signals in some physiologic domains but emphasized small studies, varied populations and regimens, and insufficient evidence for broad anti-aging conclusions. No completed randomized trial has shown that rapamycin extends human lifespan.

Limited human evidence

Claimed rapamycin benefits versus demonstrated outcomes

Online discussions often group lifespan, immune function, cognition, cardiovascular prevention, cancer prevention, and ovarian aging under a single “anti-aging” claim. These are distinct outcomes and cannot be inferred from one mechanism or one small study.

Some short human studies have reported changes in selected immune or physiologic measures. A biomarker or vaccine-response finding is not the same as demonstrating fewer age-related diseases, better day-to-day function, or longer life.

Not established

What is not proven

  • That rapamycin extends human lifespan
  • That it prevents dementia, cardiovascular disease, cancer, or frailty in healthy adults
  • That intermittent use avoids immunosuppression or metabolic harm
  • That a particular longevity regimen has an established benefit-risk balance
  • That women in menopause receive a specific healthspan or ovarian-aging benefit

Established evidence

Rapamycin side effects and monitoring concerns

The approved sirolimus label describes infections, malignancy risk, mouth ulcers, edema, impaired wound healing, lipid elevations, blood-count changes, protein in the urine, lung toxicity, reproductive effects, and numerous interactions. Risk depends on indication, patient factors, exposure, other medicines, and clinical monitoring.

Transplant evidence cannot simply be translated into a healthy longevity population, while a lower or intermittent experimental regimen cannot be assumed to eliminate labeled harms. Long-term safety for anti-aging use remains unresolved.

Established evidence

Is rapamycin a supplement?

No. Sirolimus is a prescription immunosuppressant. Products marketed online as “rapamycin supplements” should not be assumed to contain an approved drug, meet pharmaceutical quality standards, or have evidence for longevity. This resource does not provide purchase sources.

Rapamycin cost and access searches

Cost varies by formulation, indication, insurance, pharmacy, and monitoring needs. A low advertised tablet price does not represent the total clinical cost or establish that longevity prescribing is appropriate. Kindr Health does not claim to offer rapamycin for longevity on this page.

Why this page does not include a longevity protocol

Publishing a dose schedule would overstate evidence and invite self-experimentation with a potent prescription immunosuppressant. Research protocols, transplant dosing, and anecdotal longevity practice are not interchangeable. Anyone taking sirolimus for an approved condition should follow the prescribing clinician and product label.

What people ask about Rapamune; also called rapamycin

Is rapamycin FDA approved for longevity?+

No. Sirolimus is FDA approved for specific medical uses, but not to slow aging, extend lifespan, or improve healthspan in healthy people.

Does rapamycin extend lifespan in humans?+

That has not been established. Animal studies show lifespan effects, but no completed randomized human trial has demonstrated longer lifespan.

What dose is used for longevity?+

There is no FDA-approved or evidence-established longevity dose. This page intentionally does not provide a dosing or self-administration protocol.

Is intermittent rapamycin proven safe?+

No regimen has an established long-term benefit-risk balance for longevity in healthy people. Intermittent use should not be assumed to remove labeled risks.

Is rapamycin a supplement?+

No. Sirolimus is a prescription immunosuppressant with serious labeled risks, not a dietary supplement.

What are the most important rapamycin side effects?+

The label includes infection and malignancy risk, mouth ulcers, edema, impaired wound healing, lipid and blood-count changes, kidney and lung concerns, reproductive effects, and interactions. Risk varies by clinical context.

Does Kindr Health prescribe rapamycin for longevity?+

This page does not claim or imply that rapamycin is available through Kindr Health.

Education, not a medication offer

Kindr Health does not claim to offer Rapamune; also called rapamycin on this page. Availability and prescribing are not implied.

SOURCES & REFERENCES

Every clinical claim on this page is sourced.

  1. RAPAMUNE (sirolimus) prescribing information (2022) — U.S. Food and Drug Administration. www.accessdata.fda.gov/drugsatfda_docs/label/2022/021083s069s070%2C021110s087s088lbl.pdf
  2. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice (2009) — Nature. pubmed.ncbi.nlm.nih.gov/19587680
  3. Safety and efficacy of rapamycin on healthspan metrics in humans: a systematic review (2024) — The Lancet Healthy Longevity. pubmed.ncbi.nlm.nih.gov/38388333
  4. mTOR inhibition improves immune function in the elderly (2014) — Science Translational Medicine. pubmed.ncbi.nlm.nih.gov/25540326

This resource is educational and does not replace individualized medical advice. Do not start, stop, or change a prescription without guidance from a licensed healthcare professional.